Drug DevelopmentThe company's drug development engine could continue to add new products to the pipeline, reinforcing its potential in the market.
Pipeline StrengthPraxis has the most impressive pipeline in epilepsy across DEEs, FOS, and generalized seizures.
Study ResultsInvestor feedback suggests that successful results in the study could lead to a positive stock move of 20% or more.